蔗糖铁不同给药方案对尿毒症患者肾性贫血的疗效影响分析

目的探讨蔗糖铁不同给药方案对治疗尿毒症患者肾性贫血的临床效果及安全性。方法选取尿毒症肾性贫血患者183例,随机分为两组。两组患者均在透析治疗的同时给予促红细胞生成素治疗,并通过蔗糖铁静脉给药的方法补充铁剂,使铁参数达到目标值后对照组停止使用蔗糖铁12周;观察组继续给予蔗糖铁静脉给药,每（1~2）周1次。结果对照组患者停药12周后,血清铁蛋白、转铁蛋白水平均明显低于治疗前（P〈0.05）,但是血红蛋白水平差别不大（P〉0.05）;观察组患者维持治疗12周后血红蛋白水平、血清铁蛋白以及转铁蛋白水平均明显高于治疗前（P〈0.05）,且均明显高于对照组停药12周后（P〈0.05）。观察组患者显效率、有效率和总有效率分别为34.78%、56.52%和91.30%,均明显高于对照组,两组比较差异具有统计学意义（P〈0.05）。两组患者治疗耐受性良好,依从性良好,没有发现明显不良反应。结论通过蔗糖铁应用改善尿毒症患者肾性贫血状况之后,继续给予蔗糖铁维持剂量持续给药有利于维持治疗的效果,且用药安全。

Iron Sucrose Impact Analysis of Different Dosing Regimens of Uremic Patients with Renal Anemia Efficacy.

Objective To investigate iron sucrose different dosing regimens for the treatment of uremic patients with renal anemia clinical efficacy and safety. Methods Renal anemia in patients with uremia 183 cases were randomly divided into two groups so that comparable. All patients were given dialysis treatment while erythropoietin treatment and iron supplementation ad- ministered by intravenous iron sucrose way to make iron parameters after reaching the target group to stop using iron sucrose 12 weeks ; observation group to continue to give sucrose iron intravenously every （ 1 to 2） weeks. Results In the control group of patients discontinued 12 weeks, serum ferritin, transferrin Whitewater were significantly lower than before treatment（ P 〈 0. 05 ） , but little difference in hemoglobin levels （P 〉 0.05 ） ;observation group were maintained for 12 weeks after hemoglobin levels, serum ferritin and transferrin Whitewater average significantly higher than before treatment （ P 〈 0. 05 ） , and were significantly higher withdrawal after 12 weeks （P 〈 0. 05）. The observation group were markedly effective, efficient and total efficiency were 34.78% , 56. 52% and 91.30% , were significantly higher, the difference was statistically significant（ P 〈 0. 05 ）. Two groups of patients tolerated the treatment well, good compliance, found no significant adverse reactions. Conclusion After improving the condition of renal anemia in patients with uremia by iron sucrose applications continue to provide ongoing maintenance dose administered iron sucrose in favor of maintaining the effects of treatment, and drug safety.